Navigation Links
Cardiome To Release Third Quarter Results
Date:11/12/2007

on of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at http://www.sec.gov and the Canadian securities regulatory authorities at http://www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by t
'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cardiome to Present at Bear Stearns Conference
2. Cardiome to Present at ThinkEquity Conference
3. Cardiome to Present at CIBC Conference
4. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
5. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
6. First New York/New Jersey Health Care Report Card Released
7. Cleveland Clinic Press Releases Journal-Writing Book Write for Life: Healing Body, Mind, and Spirit Through Journal Writing by Sheppard B. Kominars, Ph.D.
8. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
9. Leading Child Abuse Center Releases Back to School Tips to Protect Children From Internet Predators
10. Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference
11. JHA Releases 2007 U.S. Group Disability Mid-Year Market Survey Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Rocky Mountain Oils, a leading non-MLM supplier ... added a new CEO, Mr. Darold Francis. The changes will help enhance the company’s ... that customers have come to know and respect for over eight years. , “I ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... manager of HRA Healthcare Research & Analytics , a consultative healthcare market ... Inc. (MJH) family of businesses. HRA offers quantitative and qualitative, custom and multi-client ...
(Date:6/30/2015)... Los Angeles, CA (PRWEB) , ... June 30, ... ... Physicians News Digest discussed the advantages that fat transfer procedures had ... breast reconstruction using fat transfer techniques create breasts that “look and feel natural,” ...
(Date:6/30/2015)... ... June 30, 2015 , ... Board certified otolaryngologist Dr. Marcelo ... . , Dr. Antunes is a fellowship trained facial plastic ... In addition to performing cosmetic and reconstructive surgery on the face, he enjoys ...
(Date:6/30/2015)... ... ... James C. Wittig, MD , Vice Chairman of ... of the Skin and Sarcoma division at the John Theurer Cancer Center is ... Pathology Course. The newly installed lectures are designed to education patients, students, ...
Breaking Medicine News(10 mins):Health News:Rocky Mountain Oils Adds New CEO, Announces Relocation of Operations to Orem, Utah 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 3Health News:Atlanta Otolaryngologist Dr. Marcelo Antunes Joins Northwest ENT and Allergy Center 2Health News:Atlanta Otolaryngologist Dr. Marcelo Antunes Joins Northwest ENT and Allergy Center 3Health News:NJ Top Doc, Dr. James C. Wittig, has Enhanced his Education Portal on TumorSurgery.org 2Health News:NJ Top Doc, Dr. James C. Wittig, has Enhanced his Education Portal on TumorSurgery.org 3
... New research found only 45 percent of players return to same or higher ... ... percent of baseball,players were able to return to the game at the same ... during,the 2008 American Orthopaedic Society for Sports Medicine Specialty Day at,The Moscone Center., ...
... The Associated Press will,publish a series of ... of pharmaceuticals in drinking water. While the issue ... not new, the series,may prompt concern among consumers. ... Works Association (AWWA), issued the following,statement:, "The ...
... - AstraZeneca and Bristol-Myers Squib - not part of ... ... Today eleven major pharmaceutical,companies, including Abbott Laboratories (NYSE: ABT ... million nationwide settlement,in the average wholesale price (AWP) litigation filed in ...
... March 7 The following statement is,from Hughes Hubbard ... LLP:, United States District Judge Eldon E. Fallon ... Deputy Special Masters who will decide,any appeals taken from ... program for Vioxx product liability litigation in the,United States, ...
... for,International Development and USAID Administrator Henrietta Fore hosted,Mrs. ... Women,s Day,celebration today. The internationally recognized day is ... the world and inspire all,women to achieve their ... reminder,of the continued action that is required to ...
... named 13 translational researchers as the 2008 recipients ... The awards, which provide $150,000 per year ... established, independent physician-scientists who are dedicated to translational ... treatmentand mentoring physician-scientist trainees. , The award ...
Cached Medicine News:Health News:Comeback to a Pre-Injury Level After Elbow or Shoulder Surgery Disappointing for Pro Baseball Players 2Health News:Hagens Berman: Eleven Defendants Settle in Average Wholesale Price Litigation 2Health News:Hagens Berman: Eleven Defendants Settle in Average Wholesale Price Litigation 3Health News:Special Masters Appointed in Program to Resolve U.S. VIOXX(R) Product Liability Lawsuits 2Health News:Special Masters Appointed in Program to Resolve U.S. VIOXX(R) Product Liability Lawsuits 3Health News:Special Masters Appointed in Program to Resolve U.S. VIOXX(R) Product Liability Lawsuits 4Health News:First Lady Honors Women at International Women's Day Event 2Health News:Burroughs Wellcome Fund grants $9.75 million towards translational researchers 2
(Date:6/29/2015)... , June 29, 2015  New guidelines ... American Stroke Association give hope for better outcomes ... experience an acute ischemic stroke each year. Stryker,s ... key products used in the clinical trials that ... new AHA/ASA guidelines strongly recommend endovascular therapy with ...
(Date:6/29/2015)... 2015  Nevro Corp. (NYSE: NVRO ), a ... solutions for the treatment of chronic pain, today announced ... Officer of Intersect ENT (NASDAQ: XENT ), has ... 28, 2015. For the last seven ... ENT, a company dedicated to improving the quality of ...
(Date:6/29/2015)... ZIONA, Israel , June ... (Nasdaq: BVXV, TASE: BVXV) today announced positive preliminary results ... BiondVax,s candidate for a universal influenza vaccine. In this ... ages of 50 to 65, followed by an administration ... weeks later. M-001 was found to be safe and ...
Breaking Medicine Technology:New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 2New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 3Nevro Appoints Lisa Earnhardt to its Board of Directors 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3
... 2011 /PRNewswire-Asia/ -- Pharmaceutical company Hatchtech Pty Ltd has ... study to confirm the efficacy of its novel head ... is evaluating the efficacy, safety and tolerability of two ... to vehicle. The trial consists of treating 132 healthy ...
... Aug. 31, 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ... appointed Helen Torley, M.B. Ch. B., M.R.C.P.,  as Executive ... Dr. Torley will report to N. Anthony Coles, M.D., ... for all commercial activities related to Nexavar and the ...
Cached Medicine Technology:Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™ 2Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™ 3Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer 2Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer 3
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Each handle is designed to fit a specific trephine size....
Medicine Products: